Savings From Part B Rx Price Substitution Are Small, But Worth Getting – OIG
This article was originally published in The Pink Sheet Daily
Executive Summary
HHS Office of Inspector General says CMS’ price substitution policy for drugs exceeding 5% in ASP/AMP pricing differential would have saved Medicare $7 million in 2011, less than a tenth of a percent of total Part B drug spending, CMS does not concur with OIG recommendations to help increase savings.